Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
Jean-Baptiste Trouiller, Georgios F. Nikolaidis, Bérengère Macabeo, Nicolas Meyer, Laetitia Gerlier, Max Schlueter, Philippe Laramee
| Year of publication: |
2024
|
|---|---|
| Authors: | Trouiller, Jean-Baptiste ; Nikolaidis, Georgios F. ; Macabeo, Bérengère ; Meyer, Nicolas ; Gerlier, Laetitia ; Schlueter, Max ; Laramee, Philippe |
| Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 25.2024, 4, p. 641-653
|
| Subject: | BRAF | Cost-effectiveness | Economic analysis | Encorafenib | QALY | Unresectable or metastatic melanoma | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Theorie | Theory | Gesundheitsökonomik | Health economics | Kosten-Nutzen-Analyse | Cost-benefit analysis | Gesundheitskosten | Health care costs | Effizienz | Efficiency |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-023-01614-6 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10014565059